Target Price | $42.84 |
Price | $25.75 |
Potential |
66.37%
register free of charge
|
Number of Estimates | 16 |
16 Analysts have issued a price target Beam Therapeutics Inc 2026 .
The average Beam Therapeutics Inc target price is $42.84.
This is
66.37%
register free of charge
$84.00
226.21%
register free of charge
$20.20
21.55%
register free of charge
|
|
A rating was issued by 21 analysts: 18 Analysts recommend Beam Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Beam Therapeutics Inc stock has an average upside potential 2026 of
66.37%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 63.52 | 44.50 |
83.18% | 29.94% | |
EBITDA Margin | -619.71% | -1,045.38% |
1,395.95% | 68.69% | |
Net Margin | -593.10% | -1,001.30% |
1,590.35% | 68.82% |
17 Analysts have issued a sales forecast Beam Therapeutics Inc 2025 . The average Beam Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Beam Therapeutics Inc EBITDA forecast 2025. The average Beam Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Beam Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Beam Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.58 | -4.42 |
166.28% | 3.49% | |
P/E | negative | |
EV/Sales | 32.69 |
18 Analysts have issued a Beam Therapeutics Inc forecast for earnings per share. The average Beam Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Beam Therapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
Barclays |
Locked
➜
Locked
|
Locked | May 07 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | May 07 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | May 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
Barclays:
Locked
➜
Locked
|
May 07 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
May 07 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
May 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 28 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.